TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
17/07/2025
Voltar para busca
Dado oficial do USPTO
SERCA PHARMACEUTICALS
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
46
Atualização mais recente
23/07/2025
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
5, 35, 40, 42
Data de depósito
20/12/2021
Data de registro
14/11/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
14/11/2023
Última transação
23/07/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
NO
Examinador
SEVERSON, JUSTIN
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a heart design made up of two curved bands, to the left of the term "SERCA" above "PHARMACEUTICALS.
Titulares e representantes
Titulares
S. A. (pessoa física)
Representantes
Susan Stabe Kutak Rock LLP
Classificação técnica
Classes Nice
Classe 5Classe 35Classe 40Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
pharmaceutical preparations for treatment of cardiovascular diseases; pharmaceutical preparations for treatment of myocardial infarction; pharmaceutical preparations for prophylactic treatment of cardiovascular diseases; pharmaceutical preparations for prophylactic treatment of myocardial infarction; cardiovascular disease prophylactic preparations for preventing cardiovascular disease; myocardial infarction prophylactic preparations for preventing myocardial infarction
Classe 35
Promoting of pharmaceutical products; retail stores services featuring pharmaceutical products; promoting of pharmaceutical products for therapeutic treatment of cardiovascular diseasesproducts for therapeutic treatment of myocardial infarctionproducts for prophylactic treatment of cardiovascular diseases and products for prophylactic treatment of myocardial infarction; retail store services featuring pharmaceutical products for therapeutic treatment of cardiovascular diseasesproducts for therapeutic treatment of myocardial infarctionproducts for prophylactic treatment of cardiovascular diseases and products for prophylactic treatment of myocardial infarction; promoting of cardiovascular disease prophylactic preparations and myocardial infarction prophylactic preparation; retail store services featuring cardiovascular disease prophylactic preparations and myocardial infarction prophylactic preparation
Classe 40
Treatment of materials for use in production of pharmaceuticals; production and custom manufacturing of pharmaceuticals; production and custom manufacturing of preparations for treatment of cardiovascular diseasespreparations for treatment of myocardial infarctionpreparations for prophylactic treatment of cardiovascular diseases and preparations for prophylactic treatment of myocardial infarction; production and custom manufacturing of cardiovascular disease prophylactic preparations and myocardial infarction prophylactic preparations
Classe 42
Research and development of pharmaceutical preparations for treatment of cardiovascular diseasespreparations for therapeutic treatment of myocardial infarctionpreparations for prophylactic treatment of cardiovascular diseases and preparations for prophylactic treatment of myocardial infarction; research and development of cardiovascular disease prophylactic preparations and myocardial infarction prophylactic preparations
Publicações
Histórico de despachos e eventos da marca no USPTO.
46 publicações encontradas
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
17/07/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
17/07/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
17/07/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/02/2025
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
24/01/2025
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
24/01/2025
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
24/01/2025
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
24/01/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/11/2024
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/03/2024
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/02/2024
FIMP
FINAL DISPOSITION PROCESSED
14/02/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
14/02/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
14/11/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
14/11/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
29/08/2023
PUBO
PUBLISHED FOR OPPOSITION
29/08/2023
GPNX
NOTIFICATION PROCESSED BY IB
28/08/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/08/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
09/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/08/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
27/07/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/07/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/07/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/07/2023
GPRN
NOTIFICATION OF PRIORITY ACTION E-MAILED
13/04/2023
GPRA
PRIORITY ACTION E-MAILED
13/04/2023
CPRA
PRIORITY ACTION WRITTEN
13/04/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/03/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
15/03/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
15/03/2023
RFNT
REFUSAL PROCESSED BY IB
28/12/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/12/2022
RFRR
REFUSAL PROCESSED BY MPU
07/12/2022
ATRV
ATTORNEY REVIEW COMPLETED
17/11/2022
CREV
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
26/10/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
07/10/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
27/09/2022
CNRT
NON-FINAL ACTION WRITTEN
26/09/2022
DOCK
ASSIGNED TO EXAMINER
26/09/2022
CRCV
CORRECTION TRANSACTION RECEIVED FROM IB
23/07/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
28/05/2022
MAFR
APPLICATION FILING RECEIPT MAILED
19/02/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
15/02/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/02/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SERCA PHARMACEUTICALS ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.